Table 1.
Baseline demographic and clinical characteristics of the trial participants
| Usual care (n=27) | Exercise (n=24) | All (n=51) | ||
| Age (years) | 65±11 | 59±13 | 63±12 | |
| Sex (n, %) | Female | 5 (19%) | 7 (29%) | 12 (23.5%) |
| Ethnicity (n, %) | White | 12 (44%) | 11 (46%) | 23 (45%) |
| Asian or Asian British | 11 (41%) | 11 (46%) | 22 (43%) | |
| Caribbean | 1 (4%) | 0 (0%) | 1 (2%) | |
| Other ethnic | 1 (4%) | 1 (4%) | 2 (4%) | |
| Not stated | 2 (7%) | 1 (4%) | 3 (6%) | |
| Diagnosis (n, %) | Aetiology uncertain | 8 (29%) | 7 (29%) | 15 (29%) |
| Diabetic nephropathy | 5 (19%) | 7 (29%) | 12 (23%) | |
| Glomerulonephritis | 5 (19%) | 3 (14%) | 8 (16%) | |
| Renal vascular disease | 3 (11%) | 2 (8%) | 5 (10%) | |
| Other diagnoses | 4 (15%) | 1 (4%) | 5 (10%) | |
| Chronic pyelonephritis | 2 (7%) | 1 (4%) | 3 (6%) | |
| Polycystic kidney disease | 0 (0%) | 2 (8%) | 2 (4%) | |
| Not recorded | 0 (0%) | 1 (4%) | 1 (2%) | |
| CCI | 5±2 | 5±2 | 5±2 | |
| Previous transplant (n, %) | No | 21 (78%) | 18 (75%) | 39 (76.5%) |
| Yes | 6 (22%) | 6 (25%) | 12 (23.5%) | |
| Time on HD (months) | 17 (7–53) | 13 (10–61) | 16 (8–53) | |
| BMI (kg/m2) | 27.38±6.72 | 25.87±5.28 | 26.67±6.07 | |
| Total no. medications | 12±4 | 12±4 | 12±4 | |
| Clinical information | Albumin (g/L) | 35.4±4.4 | 37.4±4.3 | 36.4±4.4 |
| Haemoglobin (g/L) | 107±12 | 112±17 | 107±15 | |
| Haemodialysis | URR (%)* | 74 (70–80) | 75 (58–79) | 74 (71–79) |
| SBP (mm Hg) | 143±21 | 144±21 | 144±21 | |
| DBP (mm Hg)* | 65 (62–78) | 78 (69–86) | 76 (62–81) | |
| CFS (n, %) | 4, vulnerable | 13 (48%) | 10 (42%) | 23 (45%) |
| 5, mildly frail | 5 (18.5%) | 7 (29%) | 12 (23.5%) | |
| 6, moderately frail | 8 (30%) | 5 (21%) | 13 (25.5%) | |
| 7, severely frail | 1 (3.5%) | 2 (8%) | 3 (6%) |
Values reported are mean and SD (±), except for *median and IQR.
BMI, body mass index; CCI, Charlson Comorbidity Index; CFS, Clinical Frailty Scale; DBP, diastolic blood pressure; SBP, systolic blood pressure; URR, urea reduction ratio.